Navigation Links
Free Prostate Cancer Seminar in Lake Ridge, VA: Dr. Charles 'Snuffy' Myers Announces Vitamin D Clinical Trials
Date:4/16/2008

CHARLOTTESVILLE, Va., April 16 /PRNewswire-USNewswire/ -- The Foundation for Cancer Research and Education (FCRE) announced today that prostate cancer oncologist and survivor, Dr. Charles "Snuffy" Myers, will lecture on new treatments for prostate cancer at Westminster at Lake Ridge, VA on April 26, 2008 from 9:30 AM--12:30 PM.

"With the recent press around prostate cancer vaccines, people are very excited about new treatments," Myers says. "The good news is there are many things people can do to prevent recurrence before it starts."

Some of those treatments include:

-- Celebrex

-- Proscar/Avodart

-- Leukine

-- Calcitriol

-- Avastin

-- Mediterranean heart healthy diet

-- Vitamin D3

-- Pomegranate.

In addition, to his lecture, Dr Myers will also be announcing his new clinical trials meant to investigate one of the most promising of those treatments -- vitamin D3.

"The current research and what I see in my patients suggests that vitamin D can dramatically slow the PSA doubling times that indicate recurrent and often lethal disease," Myers says. "The trials are meant to show Vitamin D3's role in slowing or stopping the growth of prostate cancer that has recurred after surgery or radiation in a much more substantive way." Information about the trial and how to participate will be provided at the meeting.

The program, located at Westminster at Lake Ridge, 12191 Clipper Drive, Lake Ridge or Woodbridge, VA, is free of charge and includes a heart-healthy buffet breakfast for all attendees. Sponsors include FCRE, The Virginia Prostate Cancer Coalition, Us TOO, Westminster at Lake Ridge, and Potomac Hospital.

This will be the fourth time Myers has presented at Lake Ridge but the first time he publicly announces the foundation's new research efforts.

"Myers's always provides informative lectures," notes Richard Gillespie, head of the Lake Ridge Us TOO Chapter. "But we're eager to hear about the new trials Dr. Myers is working on."

For information on the event or directions please call Richard Gillespie at 703-497-0628.

About FCRE

The Foundation for Cancer Research and Education (FCRE) is dedicated to cutting edge research and clinically driven educational programs. A streamlined organization with specific research goals, FCRE's mission is to prolong patients' lives with focused research strategies. For more information or for a list of FCRE's outreach programs call 800-305-2432 or go to http://www.cancer-foundation.org.


'/>"/>
SOURCE Foundation for Cancer Research and Education
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
3. Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
6. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
7. Study Suggests Soy Protein May Reduce Prostate Cancer Risk
8. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
9. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
10. Prostate Cancer Treatment Centre Receives Funding for Clinical Trials
11. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/12/2017)... Sept. 12, 2017   EcoVadis , the leading platform for environmental, ... first annual edition of its Global CSR Risk and Performance Index. The ... EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points across ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... Milwaukee, WI (PRWEB) , ... October 13, 2017 , ... ... movement in medicine known as “patient engagement.” The patient is doing more than filling ... research partners. , “There is an increasing emphasis in health care and research ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association of ... of excellence for the field of eating disorders, announces the opening of early ... in Orlando, Florida at the Omni Resort at ChampionsGate. , The ...
(Date:10/13/2017)... ... , ... Lori R. Somekh, founder of the Law Office of Somekh ... law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up ... network with elder law attorneys nationwide,” said Somekh. , ElderCounsel was ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset ... of specialty vendors and unique items from across the nation, this holiday-themed event will ... services offered by the VNA. The boutique will be open Saturday, November 4 ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
Breaking Medicine News(10 mins):